Aspire Biopharma Holdings, Inc. financial data

Symbol
ASBP, ASBPW on Nasdaq
Location
194 Candelaro Drive, #233, Humacao, PR
Fiscal year end
December 31
Latest financial report
10-Q/A - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 15.3 % +340%
Debt-to-equity -118 % +82.8%
Return On Equity 269 % +123%
Return On Assets -1.49K % -28727%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 107M shares
Common Stock, Shares, Outstanding 49.5M shares
Entity Public Float 87M USD +363%
Common Stock, Value, Issued 4.95K USD
Weighted Average Number of Shares Outstanding, Basic 49.5M shares +79.4%
Weighted Average Number of Shares Outstanding, Diluted 49.5M shares +79.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 208K USD +2870%
Selling and Marketing Expense 425K USD +2451%
General and Administrative Expense 18.7M USD +2194%
Operating Income (Loss) -1.15M USD -432%
Nonoperating Income (Expense) -11.8M USD -4026%
Income Tax Expense (Benefit) 1.01K USD
Net Income (Loss) Attributable to Parent -20.5M USD -2855%
Earnings Per Share, Basic -0.04 USD/shares -300%
Earnings Per Share, Diluted -0.04 USD/shares -300%

Balance Sheet

Label TTM Value / Value Unit Change %
Inventory, Net 35.4K USD
Assets, Current 2.4M USD +3788%
Assets 2.4M USD -63.9%
Accounts Payable, Current 1.06M USD
Accrued Liabilities, Current 267K USD
Liabilities, Current 13.9M USD +111%
Liabilities 13.9M USD +111%
Retained Earnings (Accumulated Deficit) -22.6M USD -46.7%
Stockholders' Equity Attributable to Parent -11.5M USD -1381%
Liabilities and Equity 2.4M USD -63.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.75M USD -808%
Net Cash Provided by (Used in) Financing Activities 3.09M USD +1251%
Common Stock, Shares Authorized 490M shares
Common Stock, Shares, Issued 49.5M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.34M USD +3619%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.95M USD +11678%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares +100%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 11.1M USD +25%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%